Our pipeline
Toragen’s lead program targets the E5 protein of Human Papillomavirus (HPV) to potentially treat HPV-induced cancers.
Our target
HPV E5
- E5 is one of eight genes of HPV
- E5 is a known oncogene
E5 Actions
- E5 downregulates surface MHC expression, stimulates cell proliferation, and prevents differentiation
Our Drug Candidates
TGN-S11 and TGN-S15
TGN-S11 and TGN-S15 inhibit E5 to restore the MHC presentation to the cell surface which then signals the T-cells to eliminate the infected cell